Appeal — TEST-CLAIM-00021

Date: [Date of Submission]

Synthetic UHC
Appeals and Grievances Department
[Payer Address]

Re: Formal Appeal of Claim Denial
External Claim ID: TEST-CLAIM-00021
Internal Claim Reference: 6c19da70-ff12-494a-a9d4-3af1287a82c0
Payer: Synthetic UHC
Date of Service: 2026-03-26
Procedure Code(s): CPT 69829
Diagnosis Code(s): ICD-10 R07.85
Denial Date: 2026-06-14
Appeal Deadline: 2026-09-12

Dear Synthetic UHC Appeals and Grievances Department,

This letter constitutes a formal first-level appeal on behalf of our facility regarding the denial of Claim TEST-CLAIM-00021. We respectfully request that Synthetic UHC overturn the denial issued on 2026-06-14 under denial code CO-55, which classified CPT 69829 (tympanoplasty with ossicular reconstruction) as experimental or investigational, and that the claim be reprocessed for payment of the denied amount.

I. STATEMENT OF THE DENIAL AND BASIS FOR APPEAL

Synthetic UHC denied Claim TEST-CLAIM-00021 under CO-55, asserting that the procedure performed on 2026-03-26 — CPT 69829, tympanoplasty with ossicular reconstruction — constitutes an experimental or investigational treatment under the payer's coverage criteria. We respectfully but firmly contest this determination. CPT 69829 is a well-established, widely performed otologic surgical procedure that has received FDA clearance and approval, is supported by an extensive body of peer-reviewed clinical literature, and is recognized as a standard of care in otolaryngology. The factual and clinical basis for the CO-55 classification does not withstand scrutiny, and the denial should therefore be overturned.

II. CLINICAL AND REGULATORY BASIS FOR APPEAL

CPT 69829 represents a category of otologic surgery — tympanoplasty with ossicular chain reconstruction — that has been performed routinely by otolaryngologists for decades. This procedure is not novel, unproven, or subject to ongoing investigational review. Specifically:

• FDA Clearance/Approval: The surgical techniques, instruments, and implantable devices associated with ossicular reconstruction carry FDA clearance and/or approval. As documented in the enclosed clinical evidence supporting non-experimental status, including FDA clearance and approval documentation, this procedure operates squarely within the regulatory framework governing approved medical practice.

• Peer-Reviewed Literature: The enclosed clinical evidence includes peer-reviewed publications from recognized otolaryngology and otologic surgery journals affirming that tympanoplasty with ossicular reconstruction is a mature, evidence-based intervention in standard clinical use for appropriate otologic indications.

• Standard Clinical Adoption: The procedure is included in the standard curriculum and credentialing framework for board-certified otolaryngologists, is listed in widely accepted coding and clinical references without investigational designation, and is routinely reimbursed by Medicare and other major payers as a covered surgical benefit.

• Medical Necessity for This Patient: The enclosed letter of medical necessity from the treating physician, the operative report, and the patient's medical history and clinical presentation collectively demonstrate that CPT 69829 was clinically indicated for this patient's documented otologic condition and was performed in accordance with accepted standards of care.

III. APPLICABLE PAYER POLICY

Synthetic UHC's experimental/investigational exclusion is intended to restrict coverage of treatments that lack sufficient clinical evidence, regulatory approval, or acceptance within the broader medical community. CPT 69829 satisfies none of the criteria that would trigger this exclusion. We respectfully direct Synthetic UHC's reviewers to the payer's own coverage policies or medical policy documents addressing CPT 69829, enclosed herewith, which we assert do not support an experimental or investigational classification for this procedure when performed for an established otologic indication. Should the payer's internal medical policy have been applied incorrectly or inconsistently, we request that this appeal trigger a thorough internal review of the applicable policy language and its proper application to this claim.

IV. SUPPORTING DOCUMENTS ENCLOSED

The following documents are enclosed in support of this appeal:

1. Letter of medical necessity from the treating physician
2. Clinical evidence supporting non-experimental status, including peer-reviewed publications and FDA clearance/approval documentation
3. Operative report detailing the procedure performed on 2026-03-26
4. Patient's medical history and clinical presentation supporting the documented indication
5. Payer's own coverage policies or medical policy documents addressing CPT 69829
6. Evidence of procedure adoption and use in standard clinical practice

V. REQUESTED REMEDY

Based on the foregoing, we respectfully request that Synthetic UHC:

1. Overturn the CO-55 denial for Claim TEST-CLAIM-00021 in its entirety;
2. Reprocess the claim under the applicable covered benefits for CPT 69829 performed on 2026-03-26; and
3. Issue payment of the denied amount in accordance with the contracted or allowable rate.

We are confident that a thorough review of the enclosed documentation will confirm that CPT 69829 is an established, FDA-approved procedure meeting accepted standards of care, and that the CO-55 experimental/investigational classification was issued in error. We welcome the opportunity to provide any additional clinical or administrative information that may assist in the expeditious resolution of this appeal.

Please direct all correspondence regarding this appeal to:

[Facility Name]
[Appeals Contact Name and Title]
[Address]
[Phone Number]
[Fax Number]
[Email Address]

Thank you for your prompt attention to this matter.

Respectfully submitted,

[Authorized Facility Representative Name]
[Title]
[Facility Name]
[Date of Signature]